Welcome back to the journal review. This is your walkthrough of the October twenty twenty-six issue of Dermatologic Surgery, and we've got four pieces worth your time this month — a bench science paper on sclerotherapy foam physics, a clever little educational study on how badly we all misjudge tissue sacrifice with wide excision, a case series on a reconstructive option for post-Mohs ectropion, and a comprehensive review on traumatic tattoos. Let's get into it.

First up is an original bench study out of Shandong University looking at the effect of mesh pore size on foam stability in sclerotherapy foam preparation. The clinical problem here is one you already know if you or your venous malformation colleagues use physician-compounded foam — foam sclerotherapy only works as well as the foam holds together, and a foam that collapses too quickly loses its sclerosing punch. The double syringe system is the standard way to make this foam, and prior work had already shown that dropping a mesh into that system improves stability, but nobody had systematically asked what pore size actually does to that effect. That's the gap this group set out to fill.

Methodologically, this is about as clean a bench experiment as you'll see in this journal. They made one percent polidocanol foam at a one-to-four liquid-to-air ratio — the standard clinical ratio — using a double syringe system, and they built a custom automated push-pull device to standardize the twenty cycles of agitation, specifically to eliminate the operator-to-operator variability that plagues manually compounded foam. That's a smart design choice worth flagging explicitly, because foam quality in real practice is notoriously dependent on who's making it and how fast they're pumping — removing that variable lets them isolate mesh pore size as the only thing changing. They ran six groups: a no-mesh control, and five mesh groups ranging from 40 mesh down to 160 mesh, the higher number meaning a finer, smaller-pored screen. They measured foam half-life — the time for half the foam volume to collapse — and they measured bubble diameter under light microscopy.

Statistically, they used a one-way analysis of variance with post hoc testing, and this is a good moment for a quick refresher on why that's the right tool here. When you're comparing more than two groups — and they had six — you can't just run a pile of individual t-tests against each other, because each individual test carries its own small chance of a false positive, and running many of them stacks those chances up until you're fairly likely to find a "significant" difference somewhere by pure chance. An analysis of variance instead asks a single question first: is there more variation between the group means than you'd expect from random noise within groups alone? Only if that global test is positive do you then run post hoc comparisons to figure out which specific groups differ, with those post hoc methods built to keep the overall false-positive rate under control. That's exactly the right sequence for a six-arm bench comparison like this one.

The results were about as clean as the methods. Every mesh group had a significantly longer foam half-life than the no-mesh control, and the effect was clinically meaningful, not just statistically so — half-life went from around four minutes with no mesh up to nearly five minutes with the finest mesh tested. There was a clear inverse dose-response: as pore size shrank, half-life crept up, topping out at roughly five minutes with the 160 mesh screen, the finest one tested. Bubble morphology told the same story — average bubble diameter dropped by somewhere between forty-five and sixty-six percent across the mesh groups compared with control, meaning you go from a coarse average bubble around two hundred microns down into the sixty-to-hundred-ten micron range, with more uniform sizing. Smaller, more uniform bubbles mean more surface area relative to volume, which physically slows coalescence and collapse — that's the proposed mechanism, and it's a sensible one grounded in basic foam physics.

Now the honest limitations, and the authors are upfront about them. First, there's a real practical ceiling — the finer the mesh, the more force it takes to push the syringe, and beyond 160 mesh it becomes genuinely difficult to actuate quickly by hand, which is why they land on 40 to 160 mesh as the clinically feasible range rather than just chasing the smallest pore size for its own sake. Second, this was done exclusively with one percent polidocanol — whether this holds for sodium tetradecyl sulfate or other polidocanol concentrations is untested, and different sclerosants have different surface tension and viscosity profiles that could change the picture. And third — this is the big one for you as a clinician — this is a pure stability and morphology study. There's no injection feel, no controllability, no operative time, and critically no clinical efficacy or recurrence data tied to mesh use. It's bench physics, not a clinical trial.

So where does that leave you practically. This is a genuinely low-cost, low-barrier modification — dropping an inexpensive mesh filter into your double syringe connector — and the physics case for improved stability is solid and reproducible. If you or colleagues in vascular anomaly treatment are compounding your own foam, this is worth adopting as a simple bench-validated tweak. But call it promising-and-plausible rather than practice-changing in the full sense, since nobody has yet shown that longer half-life and smaller bubbles translate into better sclerosing outcomes or safety in actual patients.

Next is a cross-sectional educational study out of Geisinger, and this one is a quick, clever piece of self-assessment for our own field: quantifying knowledge gaps in tissue sacrifice and scar length among dermatologists. The background premise is one you'll recognize instantly — we all talk about Mohs being more tissue-sparing than wide local excision, but nobody actually quantifies that advantage in training or in clinic. Scar length gets discussed with patients constantly, and it even factors into billing, but the actual area of tissue removed essentially never gets calculated. The authors wanted to know whether dermatologists — residents and attendings alike — can accurately estimate that difference, or whether there's a real knowledge gap worth addressing.

The design is a single-center cross-sectional quiz, seventeen participants total, six attendings and eleven residents. They were given two basal cell carcinoma scenarios — a six-millimeter and a three-millimeter lesion — and asked to estimate scar length and tissue sacrifice comparing wide local excision with four-millimeter margins against Mohs with two-millimeter margins, using the standard three-to-one length-to-width rhomboid excision convention. The true values were back-calculated using an established geometric formula for rhomboid excision area. Residents then got a brief educational session reviewing those formulas and the underlying math, and were retested on tissue sacrifice estimation one week later; attendings weren't retested, serving instead as an untrained benchmark. This is essentially an uncontrolled pre-post educational design — the authors don't frame it this way explicitly, but it's worth naming as the likely rationale: with a sample this small, a single-arm before-and-after comparison is really the only feasible way to get a quick read on whether a brief teaching intervention moves the needle, even though it can't fully separate the effect of the lesson from simple repeat-testing familiarity.

One statistical concept worth pausing on here is the metric they used to score accuracy — root-mean-squared error, or RMSE. This is just a way of summarizing how far off people's estimates were from the true value, but instead of simply averaging the errors — which would let a big overestimate and a big underestimate cancel each other out — you square each error first, average those squared errors, then take the square root. That squaring step disproportionately penalizes big misses, and the final square root brings the number back into the original units, so an RMSE in millimeters tells you, in plain terms, roughly how far off the typical estimate was.

The actual geometry here is the real teaching point. In the six-millimeter lesion scenario, wide excision produced a scar about forty percent longer than Mohs — roughly twelve millimeters more — and removed about ninety-six percent more tissue. In the three-millimeter lesion scenario, the scar length difference was proportionally even bigger at fifty-seven percent longer, again about twelve millimeters in absolute terms, but the tissue sacrifice difference ballooned to about one hundred forty-seven percent more tissue with wide excision. That's the counterintuitive and clinically useful finding: because tissue sacrifice scales with the square of the defect diameter while margins are a fixed linear add-on, the relative tissue-sparing advantage of Mohs is actually proportionally greater for smaller lesions, not smaller.

Now, how did dermatologists do on estimating this? Scar length estimates were actually pretty good across the board — the overall average error was about a millimeter and a half, residents slightly worse than attendings, but this is a clinically trivial gap; everyone has a reasonably good intuitive feel for scar length. Tissue sacrifice was a different story entirely. The vast majority of physicians — fifteen of the seventeen, or about nine in ten — underestimated how much more tissue wide excision removes compared with Mohs. The pre-intervention area error was enormous — nearly eighty percent for residents and still over forty percent for attendings, with the whole cohort averaging around two-thirds off from the true value. After the brief educational session, though, residents' tissue sacrifice error dropped dramatically, down to under ten percent — a striking improvement from a single short teaching session.

The limitations are straightforward and the authors own them: single academic institution, only seventeen participants, no long-term retention testing to see if that improvement holds, attendings weren't retested so we don't know if the same lesson would help them equally, and the scenarios were idealized geometric calculations rather than messy real-world anatomy. So, practically, is this practice-changing? Not in the sense of altering your surgical indications — you already know Mohs spares tissue. But it is a genuinely useful, low-cost teaching tool: the quadratic relationship between defect diameter and tissue sacrifice is an underappreciated number worth having in your back pocket both for resident education and for patient counseling conversations about why Mohs matters especially for smaller lesions. File this as interesting and immediately actionable for your own teaching, even if it's not changing how you operate.

Third is a case series — a communications piece out of Barcelona and Monterrey — on using a retroauricular chondrocutaneous composite graft to repair cicatricial ectropion after Mohs surgery. No formal statistics here, so this is a straightforward presentation-and-technique-and-outcomes walkthrough. The clinical problem is one you've all seen: anterior lamellar deficit from scar contracture after lower lid or cheek Mohs defects, causing lid eversion, exposure keratitis, epiphora, and a result nobody's happy with cosmetically. The authors present nine patients treated between 2000 and 2010, ages spanning sixty to the mid-eighties, with prior diagnoses of basal cell carcinoma, squamous cell carcinoma, and one sebaceous carcinoma. All nine had developed cicatricial ectropion after various initial post-Mohs reconstructions — mostly advancement flaps, but also grafts, direct closure, and even one radial forearm free flap.

The technique itself: harvest a composite graft of skin, cartilage, and perichondrium from the retroauricular region, between the concha and antihelix, sized about twenty percent larger than the defect to account for anticipated contracture. The perichondrium is left extending a millimeter or two beyond the cartilage edge. The cicatricial tissue in the lower lid is excised to create a recipient pocket, and the graft is placed beneath the tarsal plate along the orbital rim, sutured with fine five-oh or six-oh silk, with long tails left to protect the globe, and secured with a bolster dressing. Notably, they avoid cautery in this pocket specifically to optimize healing. The donor site closes primarily with mattress sutures, no subcutaneous layer needed. Graft take here depends entirely on diffusion from the richly vascularized periocular tissue rather than any bridging phenomenon, since composite grafts — unlike full-thickness skin grafts, which revascularize from both their base and edges — depend solely on edge revascularization, which is exactly why these grafts are conventionally kept small.

Outcomes were excellent: all nine grafts took completely with no major complications, and none of the nine patients had recurrent ectropion at two-year follow-up. One patient developed a hypertrophic scar that resolved with intralesional triamcinolone. Donor sites all healed well with no reported discomfort.

In their discussion, the authors position this against the existing options. Tarsal strip and lateral canthopexy combined with flaps or grafts carry a reported failure or recurrence rate ranging widely, from about six to over forty percent in the literature. Flaps risk inadequate support and necrosis; Z-plasty is less effective in patients with significant skin elastosis and tends to leave a more visible scar; full-thickness skin grafts can contract over time and provide less structural support. The composite graft's advantage is that the cartilage component resists that contractile pull on the free margin, much as it does in nasal ala reconstruction — and the authors note this is the largest reported series specifically using this graft for post-Mohs cicatricial ectropion. They also point out the practical bonus that the retroauricular donor site is non-photoexposed, which matters in this actinically damaged patient population.

Limitations are real, though: this is a small, retrospective, single-technique case series without a comparator arm, spanning a full decade of case accrual reported well after the fact, with graft dimensions not systematically recorded. The authors also flag that significant canthal laxity or scar spanning the full eyelid diameter may need additional adjunctive procedures beyond this graft alone.

Practically, this is a solid technique to have mapped in your reconstructive toolkit for anterior lamellar deficit ectropion after Mohs — a useful, low-morbidity, well-vascularized option, particularly appealing given the hidden, non-photoexposed donor site. But given it's a nine-patient retrospective series without comparison data, think of it as an additional validated option to reach for in the right anatomic scenario, not as supplanting your existing go-to techniques like tarsal strip procedures, which still carry the more robust evidence base despite their own recurrence rates.

Last up is a review article — traumatic tattoos, prevention and treatment — and this one is a genuinely useful reference piece rather than original research, so we'll walk it the way a review deserves: what's the state of the evidence, and what does it mean for your practice. The background is familiar territory for anyone doing trauma-adjacent reconstructive work: traumatic tattooing happens when insoluble pigmented debris — road rash gravel, blast or firework particulate, graphite from pencil puncture wounds, even iatrogenic ferric subsulfate or surgical marking pen pigment — gets deposited in the dermis after abrasive, explosive, or penetrating injury, producing irregular blue-black discoloration that can be symptomatic, psychologically distressing as a reminder of the trauma, or simply cosmetically unwanted. The authors note there wasn't an up-to-date comprehensive review on managing this before now, which is the gap they're filling.

Methodologically, this is a narrative review — PubMed and Medline searched through December twenty twenty-four with a defined keyword strategy, English-language human studies only, reference lists hand-searched for additional hits. They ended up with forty-six studies total: fourteen on prevention and thirty-four on treatment of established tattoos. Worth flagging honestly up front — the evidence base here is thin. The overwhelming majority of these are uncontrolled case reports and small case series, and only three of the forty-six studies actually compared outcomes by timing of intervention or by treatment modality. So everything that follows should be read as expert-pattern synthesis from low-level evidence, not meta-analytic certainty.

On prevention: across fourteen studies and forty-five patients total, intervention windows ranged from four to forty-eight hours post-injury, using everything from simple brush debridement and dermabrasion — synthetic brush, wire brush, sandpaper, diamond fraise, even an electrocautery scratch pad — to punch excision, microsurgical extraction with small blades and microforceps under magnification, a diamond tip drill, erbium:YAG laser ablation, and Versajet hydrosurgery. The one comparative study here, from Böhler and colleagues in 1992, looked at fourteen patients treated within twenty-four hours versus a delayed group averaging around thirty-one hours, and found more residual pigmentation in the delayed group — but it's a small single-technique study, so take the signal as directional rather than definitive. The general anecdotal consensus across the literature is that under seventy-two hours is preferable, with the six-to-twenty-four-hour window considered ideal, before reepithelialization locks the pigment in.

On treatment of already-established tattoos, that's the bulk of the literature — thirty-four studies, two hundred ninety-four patients — and tattoo age in the studies that specified it ranged from as recent as three days to, strikingly, three hundred sixty-one years, meaning some of these are literal historical artifacts being presented for removal. Surgical approaches accounted for fifty-five patients across methods like dermabrasion, minipunch excision, microsurgical planing, small blade excision, a fine cutting bur, and a V-shaped curette. But laser-based treatment dominates the modern literature: ablative lasers — CO2, fractional CO2, erbium:YAG — appear in only four studies and fifty-three patients, while nonablative pigment-targeting lasers — Q-switched ruby, Q-switched alexandrite, Q-switched Nd:YAG, and picosecond devices at both seven fifty-five and ten sixty-four nanometers — dominate with twenty-three studies and two hundred thirty-four patients. That's your clear pattern-level takeaway: nonablative nanosecond or picosecond lasers are the default modern treatment of choice for established traumatic tattoos.

The one safety point that genuinely changes management, and the authors are emphatic about this: before you reach for any laser, you need to establish the nature of the embedded particulate. If there's any possibility of retained explosive or combustible material — gunpowder, firework residue, blast debris — laser energy risks igniting that material in situ, so those cases need to be steered toward nonlaser surgical or mechanical removal instead. Beyond that safety gate, skin type matters for modality selection — patients with Fitzpatrick types four through six carry a higher risk of postinflammatory pigment alteration across every treatment category, and the authors suggest that deeper-penetrating, longer-wavelength devices like a ten sixty-four nanometer Q-switched or picosecond Nd:YAG may reduce that risk relative to shorter, more melanin-targeting wavelengths like five thirty-two nanometers, with ablative and surgical approaches carrying the highest dyspigmentation risk of all in darker skin.

So practically: for the acute trauma consult, the message is simple and actionable — get foreign material out as early as possible, ideally within twenty-four hours and certainly before seventy-two, using whatever mechanical or surgical method fits the depth and extent of debris. For an established traumatic tattoo, nonablative Q-switched or picosecond lasers are your first-line tool in the absence of embedded combustible material, with wavelength selection tailored to skin type to minimize dyspigmentation risk — but always, always document and clarify the mechanism of injury before you fire a laser into old traumatic debris of unknown composition.

That wraps the October issue. A cheap mesh filter that measurably stabilizes sclerotherapy foam on the bench, a seventeen-person study reminding us we badly underestimate how much tissue wide excision actually costs compared with Mohs, a nine-patient series validating a hidden-donor-site graft for post-Mohs ectropion, and a much-needed evidence roundup on traumatic tattoos with one genuinely practice-relevant safety rule about lasers and embedded combustibles. Thanks for listening, and I'll see you next month.